Who We Are
PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.
Mission
PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.
Milestone
Seoul National University Hospital
Research Collaboration
Pre-series A Funding
Korea Investment Partners
KRW 1.5 B
Series A Funding
Korea Investment Partners, Hana Ventures, Timefolio
KRW 6 B
Bridge Funding
Korea Investment Partners, Hana Ventures, Timefolio
KRW 4.5 B
Mitochondria GMP Facility
Jung-gu, Seoul
Press Highlights
파이안바이오, 미토콘드리아 치료제 국내 1·2a상 승인
국내 1-2a상 승인 Source: https://www.hankyung.com/it/article/202106179415i
Read more >>
120억원 투자 받은 파이안바이오, 미토콘드리아 신약 임상 계획 승인
Source: https://biz.chosun.com/stock/stock_general/2021/06/17/Y2ICBHE75RHZTN3XCFO3LXGUVE/
Read more >>
IND Approval for PN-101 by MFDS
PAEAN Biotechnology, a company specializing in the development of new mitochondrial drugs, announced today that the Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug (I...
Read more >>